Clinical trials: Intestinal GVHD
Intestinal GVHD
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD
Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of novel target agents is associated with worse outcome compared to the other forms.
- Trial name
- JAK-FMT (NCT04269850)
- Testing
- allogeneic fecal microbiota, Ruxolitinib, Methylprednisone
- Where
- Russia
- Volunteers
- 2 people
- Sponsor
- St. Petersburg State Pavlov Medical University